The advancement in genetics and molecular medicine, such as epidermal growth factor receptor (EGFR), tyrosine kinase inhibitors (TKI), and anaplastic lymphoma kinase inhibitors, contributed greatly to lung cancer therapies, particularly to NSCLC (Gainor et al., 2016; Wu & Shih, 2018). This evidence concerns the gene EGFR and non-small cell lung carcinoma.